LOC147710 Inhibitors
LOC147710 Inhibitors encompass various chemical compounds that, through their action upon distinct cellular signaling pathways, can lead to the inhibition of LOC147710. Staurosporine, a broad-spectrum kinase inhibitor, can thwart ATP binding to kinases, thereby potentially impeding the phosphorylation processes that might be vital for LOC147710 function if it is phosphorylation-dependent. Similarly, Genistein and Herbimycin A, as tyrosine kinase inhibitors, as well as Lavendustin A, could obstruct tyrosine kinase signaling, which may be requisite for LOC147710's functional activation. The functional activity of LOC147710 could be diminished as a result of reduced tyrosine phosphorylation stemming from the inhibition of these kinases.
Further down the signaling cascade, compounds like Bisindolylmaleimide I target PKC, which if involved in LOC147710 regulation, would subsequently reduce its activity through diminished PKC-mediated signaling. Additionally, inhibitors like PD98059 and U0126 that specifically target the MEK enzymes in the MAPK/ERK pathway could decrease LOC147710 activity, assuming LOC147710 functions downstream of this pathway. LY294002 and Wortmannin both act as PI3K inhibitors, potentially leading to a decrease in LOC147710 activity by obstructing the PI3K/AKT signaling axis if LOC147710 is reliant upon it. The role of mTOR in cellular growth and proliferation is well-established, and thus, Rapamycin, through its inhibition of mTOR, could indirectly curtail LOC147710 activity if it is a participant or regulator within the mTOR signaling network. On a similar note, SB203580 acts on the p38 MAPK, a pathway known for its involvement in inflammatory responses and stress; inhibition here could lead to decreased LOC147710 activity if p38 MAPK signaling governs its function. Lastly, Y-27632's inhibition of ROCK, a kinase that significantly impacts the actin cytoskeleton, could affect LOC147710 if it is implicated in cytoskeletal arrangements or dynamics.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A non-selective protein kinase inhibitor that blocks ATP binding sites on kinases. Inhibition of kinases by Staurosporine leads to decreased phosphorylation of proteins, possibly including LOC147710 if its function is phosphorylation-dependent. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
An isoflavone that acts as a tyrosine kinase inhibitor. By inhibiting tyrosine kinases, Genistein can reduce tyrosine phosphorylation, which may indirectly decrease LOC147710 activity if it requires tyrosine kinase signaling for its function. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
A specific inhibitor of protein kinase C (PKC). By blocking PKC, Bisindolylmaleimide I can reduce PKC-mediated signal transduction, potentially diminishing LOC147710 activity if its function is modulated by PKC signaling. | ||||||
Herbimycin A | 70563-58-5 | sc-3516 sc-3516A | 100 µg 1 mg | $277.00 $1532.00 | 13 | |
A benzoquinoid ansamycin antibiotic that acts as a tyrosine kinase inhibitor. Herbimycin A can disrupt tyrosine kinase-mediated signaling pathways, potentially leading to decreased functional activity of LOC147710. | ||||||
Lavendustin A | 125697-92-9 | sc-200539 sc-200539A | 1 mg 5 mg | $116.00 $456.00 | ||
A tyrosine kinase inhibitor that can prevent phosphorylation by tyrosine kinases. This inhibition could lead to a decrease in LOC147710 activity if it is involved in cellular processes mediated by tyrosine phosphorylation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An MEK inhibitor that blocks the MAPK/ERK pathway. Inhibition of MEK by PD98059 can lead to reduced activation of downstream proteins, potentially leading to decreased functional activity of LOC147710 if it is part of this signal transduction pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that prevents the formation of PIP3. Inhibition of PI3K by LY294002 could lead to decreased functional activity of LOC147710 if it relies on PI3K signaling for its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can downregulate the mTOR signaling pathway. By inhibiting mTOR, Rapamycin could decrease LOC147710 activity if LOC147710 is involved in mTOR-regulated pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
An inhibitor of p38 MAPK. By blocking p38 MAPK, SB203580 can reduce the activity of downstream proteins, potentially including LOC147710 if it is regulated by p38 MAPK signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A selective inhibitor of MEK1/2, preventing ERK activation. By inhibiting MEK, U0126 could lead to a decrease in LOC147710 activity if LOC147710 is involved in the ERK signaling pathway. | ||||||